# Clinical Cases: Mycobacteria ## Case 1: Pulmonary Tuberculosis Reactivation ### Presentation A 58-year-old man presents with a 3-month history of productive cough, night sweats, low-grade fevers, and unintentional weight loss of 15 pounds. He immigrated from Vietnam 20 years ago and has no significant medical history. He denies HIV risk factors. Physical examination reveals a thin, ill-appearing man with scattered crackles in the right upper lung field. Chest radiograph demonstrates a cavitary lesion in the right upper lobe with surrounding infiltrates. Sputum smear shows numerous acid-fast bacilli. ### Clinical Image ![Chest X-ray with upper lobe cavity](image_01.png) *Chest radiograph demonstrating a cavitary lesion in the right upper lobe with surrounding parenchymal infiltrates, characteristic of reactivation pulmonary tuberculosis.* **Image Source**: Lecture image - pulmonary tuberculosis imaging ### Questions 1. **What is the most likely diagnosis, and what makes this reactivation rather than primary infection?** 2. **Why does reactivation tuberculosis typically affect the upper lobes?** 3. **What is the significance of the positive sputum smear, and what precautions are needed?** 4. **What is the standard treatment regimen for drug-susceptible pulmonary tuberculosis?** ### Answers 1. **Diagnosis and rationale**: This is **reactivation pulmonary tuberculosis** caused by **Mycobacterium tuberculosis**. The presentation is classic: chronic productive cough, constitutional symptoms (night sweats, fevers, weight loss), upper lobe cavitary disease, and positive acid-fast smear. This represents reactivation rather than primary infection because of the **upper lobe cavitary disease** pattern, the **prolonged symptom duration**, and the patient's history of immigration from an endemic area decades ago (suggesting latent infection acquired in the past now reactivating). 2. **Upper lobe predilection**: Reactivation TB characteristically involves the **posterior segments of the upper lobes** (or superior segments of the lower lobes) because these areas have the **highest oxygen tension** in the lungs due to their position at the apex with higher ventilation-to-perfusion ratios. M. tuberculosis is an obligate aerobe that thrives in oxygen-rich environments. Additionally, diminished lymphatic drainage in the apices may reduce immune surveillance. 3. **Sputum smear significance and precautions**: A positive sputum smear indicates **high bacterial burden** (requires 5,000-10,000 organisms/mL for detection) and identifies the patient as **highly infectious**. The patient requires **airborne precautions**: placement in a negative-pressure isolation room, healthcare workers must wear N95 respirators, and the patient should wear a surgical mask during transport. The patient should remain in isolation until clinical improvement is noted and typically three consecutive sputum smears (collected at least 8 hours apart) are negative. 4. **Standard treatment regimen**: The standard regimen for drug-susceptible TB is: - **Intensive phase (2 months)**: Four drugs - **R**ifampin, **I**soniazid, **P**yrazinamide, **E**thambutol (RIPE) - **Continuation phase (4 months)**: Two drugs - **R**ifampin and **I**soniazid - Total duration: **6 months** Pyridoxine (vitamin B6) supplementation should be given with isoniazid to prevent peripheral neuropathy. Direct observed therapy (DOT) is the standard of care to ensure adherence and prevent resistance development. Extension to 9 months is recommended for cavitary disease with positive sputum cultures at 2 months. --- ## Case 2: Latent Tuberculosis Before Immunosuppressive Therapy ### Presentation A 45-year-old woman with rheumatoid arthritis is being considered for adalimumab (a TNF-alpha inhibitor) therapy due to inadequate response to methotrexate. As part of pre-treatment screening, an interferon-gamma release assay (IGRA) is ordered and returns positive. She reports no symptoms of cough, fever, night sweats, or weight loss. Her chest radiograph is normal. She has no known TB exposure history but immigrated from the Philippines 15 years ago. ### Clinical Image ![Granuloma formation in TB](image_02.png) *Histopathologic section showing a granuloma with central caseous necrosis surrounded by epithelioid histiocytes, giant cells, and a lymphocyte mantle - the characteristic tissue response to M. tuberculosis.* **Image Source**: Lecture image - tuberculosis pathology ### Questions 1. **What is the diagnosis, and how does it differ from active tuberculosis?** 2. **Why is treatment of this condition particularly important before TNF-alpha inhibitor therapy?** 3. **What are the current preferred treatment regimens for this condition?** 4. **What monitoring is required during treatment?** ### Answers 1. **Diagnosis**: The diagnosis is **latent tuberculosis infection (LTBI)**. LTBI is defined as immunologic evidence of prior TB exposure (positive TST or IGRA) **without** clinical, radiographic, or microbiologic evidence of active disease. The patient is asymptomatic, has a normal chest X-ray, and would have negative respiratory cultures. Unlike active TB, patients with LTBI are **not infectious** and do not require isolation. However, LTBI represents dormant organisms that can reactivate. 2. **Importance before TNF-alpha inhibitor therapy**: **TNF-alpha is essential for granuloma formation and maintenance**. Granulomas contain M. tuberculosis infection by walling off the organisms with immune cells. TNF-alpha inhibitors disrupt this immune containment, dramatically increasing the risk of LTBI reactivation to active disease - typically **4-10 fold higher** than untreated individuals. Without LTBI treatment, patients on TNF inhibitors may develop severe, often disseminated or extrapulmonary tuberculosis. 3. **Preferred treatment regimens for LTBI**: - **3HP regimen** (preferred): Weekly isoniazid plus rifapentine for 12 doses (3 months) - highest completion rates - **4R regimen**: Daily rifampin for 4 months - isoniazid-sparing option - **6H or 9H regimen**: Daily isoniazid for 6 or 9 months - longer duration, lower completion rates Treatment should ideally be initiated **1-2 months before** starting TNF inhibitor therapy, though if the clinical situation is urgent, both can be started together. LTBI treatment should continue even after starting immunosuppression. 4. **Monitoring during treatment**: - **Hepatotoxicity monitoring**: Baseline LFTs, then monthly symptom assessment; routine LFT monitoring recommended for patients with baseline liver disease, HIV, pregnancy, or concurrent hepatotoxic medications - **Clinical assessment**: Monthly evaluation for symptoms of hepatitis (nausea, anorexia, abdominal pain, dark urine, jaundice) - **Symptoms of active TB**: Any development of cough, fever, weight loss, or night sweats requires evaluation to rule out active disease Drug should be discontinued if ALT exceeds 3x upper limit of normal with symptoms or 5x upper limit without symptoms. --- ## Case 3: Leprosy (Hansen's Disease) ### Presentation A 38-year-old man originally from Brazil presents with multiple skin lesions and numbness in his hands that have been present for over a year. He has noticed progressive weakness in his hands and difficulty gripping objects. Examination reveals numerous hypopigmented macules and plaques on the trunk, face, and extremities. Several lesions are anesthetic when tested with a monofilament. Bilateral ulnar nerve enlargement is palpable. He has loss of the outer third of his eyebrows (madarosis) and early claw hand deformity. ### Clinical Image ![Leprosy skin lesions and nerve involvement](image_03.png) *Clinical photograph showing hypopigmented skin lesions with sensory loss, thickened peripheral nerves, and early claw hand deformity characteristic of leprosy.* **Image Source**: Lecture image - Mycobacterium leprae infection ### Questions 1. **What is the diagnosis, and where does this patient fall on the clinical spectrum?** 2. **Why do skin lesions in this disease demonstrate sensory loss?** 3. **What causes the peripheral nerve enlargement and hand deformities?** 4. **What is the appropriate treatment regimen for this patient?** ### Answers 1. **Diagnosis and spectrum**: The diagnosis is **leprosy (Hansen's disease)** caused by **Mycobacterium leprae**. Based on the numerous skin lesions, bilateral nerve involvement, and systemic signs (madarosis), this patient falls toward the **lepromatous (LL)** end of the clinical spectrum - representing **multibacillary disease**. The spectrum ranges from tuberculoid leprosy (TT, paucibacillary, strong cell-mediated immunity) to lepromatous leprosy (LL, multibacillary, anergic immune response). 2. **Sensory loss mechanism**: M. leprae has a unique **predilection for cooler body tissues**, preferring temperatures of 27-30°C rather than core body temperature. Skin lesions demonstrate sensory loss because the organism **directly infects and destroys cutaneous nerves** within the lesions. The resulting damage to small nerve fibers causes anesthesia over the affected skin areas - this association of hypopigmented lesions with anesthesia is virtually pathognomonic for leprosy. 3. **Nerve enlargement and deformities**: M. leprae infects **Schwann cells** of peripheral nerves, particularly those in cooler anatomic locations (ulnar nerve at elbow, median nerve at wrist, lateral popliteal nerve, facial nerve). The resulting inflammation causes **palpable nerve enlargement**. Progressive damage leads to sensory loss, motor weakness, and autonomic dysfunction. The **claw hand deformity** results from ulnar nerve damage causing weakness of the intrinsic hand muscles and imbalance between flexors and extensors. 4. **Treatment regimen**: This patient has **multibacillary leprosy** and requires the WHO multidrug therapy regimen: - **Dapsone** daily - **Rifampin** monthly (supervised) - **Clofazimine** daily plus monthly supervised dose - **Duration: 12 months** Patients must be monitored for **leprosy reactions**: Type 1 (reversal) reactions cause acute inflammation of existing lesions and nerves (treated with corticosteroids), while Type 2 (erythema nodosum leprosum) causes systemic inflammation with skin nodules (treated with thalidomide or corticosteroids). Nerve damage during reactions can be irreversible if not treated promptly.